Yenidoğanın Vitamin Yanıtlı Nöbetlerine Yaklaşım
Özet
Yenidoğan dönemindeki nöbetler beyin gelişimi için kritik öneme sahip olup, etiyolojinin doğru belirlenmesi tedavi başarısı açısından hayati değer taşır. Piridoksin, piridoksal fosfat, folinik asit ve biyotin gibi vitaminlere yanıt veren metabolik epilepsiler, erken teşhis ve uygun tedavi ile nörolojik hasarın önüne geçilebilecek önlenebilir hastalıklardır. Bu metin, söz konusu vitamin bağımlı epileptik ensefalopatilerin klinik özelliklerini, tanısal yöntemlerini ve tedavi algoritmalarını ayrıntılı olarak incelemektedir.
Neonatal seizures are critical for neurodevelopment, making the accurate identification of their underlying etiology a primary clinical objective. Vitamin-responsive metabolic epilepsies—including those dependent on pyridoxine, PLP, folinic acid, and biotin—are treatable conditions that can be managed effectively through early diagnosis and targeted supplementation. This text details the clinical profiles, diagnostic pathways, and treatment algorithms necessary for managing these specific vitamin-responsive epileptic encephalopathies.
Referanslar
Shellhaas R. Overview of neonatal epilepsy syndromes. Nordli DR, Garcia-Prats JA ed. UpToDate. https://www.uptodate.com/contents/overview-of-neonatal-epilepsy-syndromes?search=Neonatal%20Vitamin-responsive%20Epileptic%20Encephalopathies&source=search_result&selectedTitle=4~150&usage_type=default&display_rank=4).
Abend NS, Jensen FE, Inder TE, Volpe JJ. In: Volpe JJ, (Editor-in-chief), Volpe's Neurology of the Newborn (6thed). Elsevier, Phildadelphia 2018, pp. 275-321.
Volpe JJ. Neonatal seizures. In: Volpe JJ, (ed), Neurology of the Newborn (5thed). Penn: WB Saunders, Phildadelphia 2008, pp. 203-44.
Mizrahi EM. Neoantal Seizures. In; Pellock JM, Nordli DR, Sankar R, Wheless JW. Pellock’s Petiatric Epilepsy. Fourth Ed, New York: Demos Medical Publishing; 2017, pp.489-503.
Dhamija R, Patterson MC, Wirrell EC. Epilepsy in children--when should we think neurometabolic disease? J Child Neurol 2012; 27:663.
Mastrangelo M, Cesario S. Update on the treatment of vitamin B6 dependent epilepsies. Expert Rev Neurother. 2019 Nov;19(11):1135-1147).
Gospe SM. Pyridoxine-Dependent Epilepsy – ALDH7A1. 2001 Dec 7 [updated 2021 Jul 29]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021. PMID: 20301659.
van Karnebeek CD, Tiebout SA, Niermeijer J, et al. Pyridoxine-Dependent Epilepsy: An Expanding Clinical Spectrum. Pediatr Neurol. 2016;59:6-12.
Hunt AD, Stokes J, Mc CW, Stroud HH. Pyridoxine dependency: report of a case of intractable convulsions in an infant controlled by pyridoxine. Pediatrics. 1954;13(2):140-5.
Mills PB, Struys E, Jakobs C, et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med. 2006;12(3):307-9.
Mills PB, Footitt EJ, Mills KA, et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain. 2010;133(Pt 7):2148-59.
Mefford HC, Zemel M, Geraghty E, et al. Intragenic deletions of ALDH7A1 in pyridoxine-dependent epilepsy caused by Alu-Alu recombination. Neurology. 2015;85(9):756-62.
Schmitt B, Baumgartner M, et al. Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. Dev Med Child Neurol. 2010;52(7):e133-42.
Baxter P. Pyridoxine dependent and pyridoxine responsive seizures. In: Baxter P, ed. Vitamin Responsive Conditions in Paediatric Neurology. London: MacKeith Press, 2001:109-65.
Coker S. Postneonatal vitamin B6-dependent epilepsy. Pediatrics 1992;90:221-3.
Goutières F, Aicardi J. Atypical presentations of pyridoxine- dependent seizures: a treatable cause of intractable epilepsy in infants. Ann Neurol 1985;17:117-20.
Gospe SM. Current perspectives on pyridoxine-dependent seizures. J Pediatr 1998;132:919-23.
Gospe SM. Pyridoxine-dependent seizures: findings from recent studies pose new questions. Pediatr Neurol 2002;26:181-5.
Gospe SM. Neonatal vitamin-responsive epileptic encephalopathies. Chang Gung Med J. 2010;33(1):1-12.
Kluger G, Blank R, Paul K, et al. Pyridoxine-dependent epilepsy: normal outcome in a patient with late diagnosis after prolonged status epilepticus causing cortical blindness. Neuropediatrics 2008;39:276-9.
Basura GJ, Hagland SP, Wiltse AM, Gospe SM Jr. Clinical features and the management of pyridoxinedependent and pyridoxine-responsive seizures: review of 63 North American cases submitted to a patient registry. Eur J Pediatr 2009;168:697-704.
Shih JJ, Kornblum H, Shewmon DA. Global brain dysfunction in an infant with pyridoxine dependency: evaluation with EEG, evoked potentials, MRI, and PET. Neurology 1996;47:824-6.
Nabbout R, Soufflet C, Plouin P, Dulac O. Pyridoxine dependent epilepsy: a suggestive electroclinical pattern. Arch Dis Child Fetal Neonatal Ed 1999;81:F125-9.
Alghamdi M, Bashiri FA, Abdelhakim M, et al. Phenotypic and molecular spectrum of pyridoxamine-5'-phosphate oxidase deficiency: A scoping review of 87 cases of pyridoxamine-5'-phosphate oxidase deficiency. Clin Genet. 2021;99(1):99-110.
di Salvo ML, Mastrangelo M, Nogués I, et al. Pyridoxine-5-phosphate oxidase (Pnpo) deficiency: clinical and biochemical alterations associated with the C.347g > a (P.Arg116gln) mutation. Mol Genet Metab. 2017;122(1–2):135-142.
Lugli L, Bariola MC, Ori L, Lucaccioni L, Berardi A, Ferrari F. Further Delineation of Pyridoxine-Responsive Pyridoxine Phosphate Oxidase Deficiency Epilepsy: Report of a New Case and Review of the Literature With Genotype-Phenotype Correlation. J Child Neurol. 2019;34(14):937-943.
Mohanlal S, Bindu PS, Sureshbabu S, Kumar S. Variable treatment response in a patient with pyridoxal N phosphate oxidase (PNPO) deficiency-understanding the paradox. Epilepsy & Behavior Reports. 2020;14:100357.
Mills PB, Camuzeaux SS, Footitt EJ, et al. Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome. Brain. 2014;137(Pt 5):1350-60.
Hoffmann GF, Schmitt B, Windfuhr M, et al. Pyridoxal 5’-phosphate may be curative in early-onset epileptic encephalopathy. J Inherit Metab Dis 2007;30:96-9.
Hyland K, Buist NR, Powell BR, et al. Folinic acid responsive seizures: A new syndrome? J Inherit Metab Dis 1995;18:177-81.
Frye RE, Donner E, Golja A, Rooney CM. Folinic acid–responsive seizures presenting as breakthrough seizures in a 3-month-old boy. J Child Neurol 2003;18:562-9.
Torres OA, Miller VS, Buist NM, Hyland K. Folinic acid–responsive neonatal seizures. J Child Neurol 1999;14:529-32.
Nicolai J, van Kranen-Mastenbroek VH, Wevers RA, Hurkx WA, Vles JS. Folinic acid-responsive seizures initially responsive to pyridoxine. Pediatr Neurol. 2006;34(2):164-7.
Hoffmann GF, Surtees RAH, Wevers RA. Cerebrospinal fluid investigations for neurometabolic disorders. Neuropediatrics 1998;29:59-71.
Saleem H, Simpson B. Biotinidase Deficiency. 2021 Mar 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–.
Baykal T, Hüner G, Sarbat G, Demirkol M. Incidence of biotinidase deficiency in Turkish newborns. Acta Paediatr. 1998;87:1102–1103.
Wolf B. Biotinidase deficiency: “if you have to have an inherited metabolic disease, this is the one to have”. Genet Med. 2012;14 (6):565–575.
Ferreira P, Chan A, Wolf B. Irreversibility of symptoms with biotin therapy in an adult with profound biotinidase deficiency. JIMD Rep. 2017;36:117–120.
Canda E, Yazici H, Er E, et al. Single center experience of biotinidase deficiency: 259 patients and six novel mutations. J Pediatr Endocrinol Metab. 2018;31(8):917–926.
Mastrangelo M. Actual insights into treatable inborn errors of metabolism causing epilepsy. J Pediatr Neurosci. 2018;13(1):13–23.
León-Del-Río A. Biotin in metabolism, gene expression, and human disease. J Inherit Metab Dis. 2019;42(4):647–654.
Wolf B. Biotinidase Deficiency. In: Adam MP, Ardinger HH, Pagon RA, et al. editors. GeneReviews® [Internet]. Seattle: University of Washington; 2000 March 24:1993–2019. Available from http://www. ncbi.nlm.nih.gov/books/NBK1322/. updated 2016 Jun 9.
Wolf B, Secor McVoy J. A sensitive radioassay for biotinidase activity: deficient activity in tissues of serumbiotinidase-deficient individuals. Clin Chim Acta. 1983;135(3):275–281.
Wolf B, Grier RE, Secor McVoy JR, Heard GS. Biotinidase deficiency: a novel vitamin recycling defect. J Inherit Metab Dis. 1985;8 (Suppl 1):53–58.
Seker Yilmaz B,Mungan NO, Kor D, et al. Twenty-seven mutations with three novel pathologenic variants causing biotinidase deficiency: a report of 203 patients from the southeastern part of Turkey. J Pediatr Endocrinol Metab. 2018;31(3):339–343.
Bhat MD, Bindu PS, Christopher R, Prasad C, Verma A. Novel imaging findings in two cases of biotinidase deficiency-a treatable metabolic disorder. Metab Brain Dis. 2015;30(5):1291–1294.
Desai S, Ganesan K, Hegde A. Biotinidase deficiency: a reversible metabolic encephalopathy. Neuroimaging and MR spectroscopic findings in a series of four patients. Pediatric Radiology. 2008;38 (8):848–856.
Wolf B. Clinical issues and frequent questions about biotinidase deficiency. Mol Genet Metab. 2010;100(1):6–13.
Wolf B, Heard GS, Weissbecker KA, McVoy JR, Grier RE, Leshner RT. Biotinidase deficiency: initial clinical features and rapid diagnosis. Ann Neurol. 1985;18(5):614–617.
Canda E, Kalkan Uçar S, Çoker M. Biotinidase Deficiency: Prevalence, Impact And Management Strategies. Pediatric Health Med Ther. 2020;11:127-133.
Farmania R, Gupta A, Ankur K, Chetry S, Sharma S. Complexities of pyridoxineresponse in PNPO deficiency. EpilepsyBehavRep. 2021 Apr3;16:100443.
Ficicioglu C, Bearden D. Isolated neonatal seizures: when to suspect inborn errors of metabolism. Pediatr Neurol. 2011;45(5):283-91.
